Company intelligence / Profile preview

Amaroq Therapeutics

Dunedin*, Otago, New Zealandamaroqtx.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Amaroq Therapeutics has demonstrated that targeting specific lncRNAs can slow the growth of cancer cells in preclinical research. The company has not yet entered human clinical trials but reports promising early development milestones and significant investment to support advancement toward the clinic.

Therapeutic areas: Oncology
Modalities: RNA therapeutics (targeting long non-coding RNAs, lncRNAs)Small-molecule drugs
Industry: Biotech

Partnerships

GeneCrypt (for secure genomic data management in drug discovery pipeline)

Beyond the preview

Go deeper on Amaroq Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amaroq Therapeutics.

Explore the full profile